Xtant Medical Holdings, Inc.

Xtant Medical Holdings, Inc. is a medical technology company that develops, manufactures, and commercializes regenerative biologics and spinal implant systems for surgical procedures. Headquartered in Belgrade, Montana, the company's mission is rooted in honoring the gift of tissue donation to enable patients to live full and complete lives.

The company's product portfolio includes a comprehensive range of orthobiologics, such as traditional allografts, demineralized bone matrix (DBM), synthetic bone grafts, cellular allografts, and growth factors, making it unique in offering all five categories. Key products include OsteoSponge, OsteoSelect Plus DBM putty, nanOss Strata™, CollagenX™, OsteoFactor Pro™, and Trivium™. Xtant Medical also provides spinal implant systems, including cervical and sacroiliac fusion systems, designed to work synergistically with its biologics for orthopedic and neurological surgeons, primarily in spine surgery and wound care applications.

Led by President and CEO Sean Browne, Xtant Medical has recently focused on streamlining its operations. In March 2026, the company finalized the sale of its non-core Coflex and CoFix spinal implant assets and international Paradigm Spine operations to Companion Spine for $21.4 million, aiming to sharpen its focus on higher-margin biologics. The company reported full-year 2025 revenue of $133.9 million, a 14% increase year-over-year, with a net income of $5.0 million, marking a transition to profitability. Additionally, Xtant Medical entered an exclusive U.S. distribution agreement for Dilon's HEMOBLAST® Bellows product in April 2026.